Swiss drugmaker Roche’s push into personalized cancer medicines hit a milestone with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified via genetic profiling.

Swiss drugmaker Roche upped the company’s bet on personalized cancer treatment and is ready to sell a blood test around the world that can identify common gene mutations from solid tumors from a patient’s blood.